Immune Thrombocytopenic Purpura (ITP) Clinical Trial
Official title:
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.
The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03524612 -
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
|
Phase 2 | |
| Completed |
NCT01713738 -
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 1/Phase 2 | |
| Completed |
NCT00157079 -
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
|
Phase 3 | |
| Recruiting |
NCT02877212 -
Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients
|
Phase 3 | |
| Completed |
NCT00162006 -
Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
|
Phase 2 |